← Back to Clinical Trials
Recruiting NCT05169242

NCT05169242 A Trial on Prophylactic Clipping to Prevent Post-polypectomy Bleeding After Colonoscopy in Direct Oral Anticoagulant Users

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05169242
Status Recruiting
Phase
Sponsor Chinese University of Hong Kong
Condition Post Polypectomy Bleeding
Study Type INTERVENTIONAL
Enrollment 584 participants
Start Date 2021-12-15
Primary Completion 2024-12-14

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Endoclip

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 584 participants in total. It began in 2021-12-15 with a primary completion date of 2024-12-14.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The investigators hypothesize that prophylactic clipping after colonoscopic polypectomy can reduce risk of delayed PPB among DOAC users. The investigators also hypothesize that pre-endoscopy drug level can predict the risk of hemorrhagic complications after the procedure.

Eligibility Criteria

Inclusion Criteria: * They are active users of any DOAC * They require elective colonoscopy for colorectal cancer screening, polyp surveillance, or investigation of symptoms such as anemia or past gastrointestinal bleeding * Aged 18 years old or above; * Written informed consent obtained. Exclusion Criteria: * Absolute contraindications to colonoscopy * Any medical conditions precluding interruption of DOAC for procedure * Any medical conditions requiring concomitant uninterrupted dual antiplatelet drugs (single antiplatelet drug users will not be excluded) * Active gastrointestinal bleeding * Clinically significant bleeding tendency (decompensated cirrhosis or severe thrombocytopenia) * Severe renal impairment (defined as creatinine clearance \< 15 ml/min) * Pregnancy or lactation; * Advanced comorbid conditions (defined as American Society of Anesthesiologists grade 4 or above) * Unable to obtain informed consent

Contact & Investigator

Central Contact

Louis Ho Shing Lau

✉ louishslau@cuhk.edu.lhk

📞 35052211

Frequently Asked Questions

Who can join the NCT05169242 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Post Polypectomy Bleeding. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05169242 currently recruiting?

Yes, NCT05169242 is actively recruiting participants. Contact the research team at louishslau@cuhk.edu.lhk for enrollment information.

Where is the NCT05169242 trial being conducted?

This trial is being conducted at Shatin, Hong Kong.

Who is sponsoring the NCT05169242 clinical trial?

NCT05169242 is sponsored by Chinese University of Hong Kong. The trial plans to enroll 584 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology